XBIT (XBiotech USA) Forward P/E Multiple
XBiotech Inc. (XBIT) develops antibodies to combat oncology using blood from healthy individuals. A narrow specialization in a single direction increases financial risks, as confirmed by the company's forward P/E NTM, where the value 0.00 represents the current figure. Research stability is ensured by a staff of high-caliber biologists operating on a unique technological base.
Summary analytical data breakdowns for XBiotech USA (XBIT)
- current price and projected stock value:
- business market valuation indicators:
- book capitalization information:
- issuer credit burden and liquidity indicators:
- financial results and valuation multiples details:
XBIT - Company Net Income|Future Profit XBiotech Inc.|XBIT - Market Price to Net Income Ratio|Forward P/E Multiple XBiotech Inc.|XBIT - Price to Earnings Adjusted for Growth Rate|EV/EBITDA Multiple XBiotech Inc|XBIT - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) XBiotech|XBIT - Earnings per share for the trailing year|Year-over-year net earnings per share growth for the last 12 months xbiotech.com|XBIT - Earnings per share increase in current year|Earnings growth forecast for next year XBiotech Inc.
Summary company analytics:XBiotech
The forward P/E ratio determines the cost of one unit of projected earnings, allowing for an assessment of whether market capitalization is fair relative to future cash flows. For XBiotech Inc. (XBIT), analyzing the business's forward P/E is critical, as it filters out speculative noise surrounding clinical trial data and patent risks, revealing the asset's true fundamental value amidst volatile revenue.
Competing companies
Projected Price to Earnings ONC (BeiGene)|HALO (Halozyme Therapeutics, Inc.) - Future Price to Earnings Multiple|Forward P/E Multiple RVMD (RevMed)|AAPG - Projected Price to Earnings|CGON: Projected Price to Earnings|URGN - Forward P/E Multiple|Bicara Therapeutics (BCAX) - Future Price to Earnings|Personalis Inc - Future Price to Earnings Multiple|ERAS (Erasca Corp) - Forward P/E Multiple|Projected Price to Earnings Ratio Delcath Corp DCTH|Projected Price to Earnings YMAB (Y-mAbs Therapeutics)|aurabiosciences.com - Price to Future Earnings Ratio|Forward P/E Multiple CADL (Candel Therapeutics, Inc.)|Accuray Inc - Future Price to Earnings|SELLAS Life Sciences Group Inc. - Forward P/E Multiple|Market Cap to Projected Earnings Actuate Therapeutics Inc ACTU|Citius Oncology, Inc. (CTOR) - Future Price to Earnings|Projected Price to Earnings Ratio TuHURA Biosciences (HURA)|Projected Price to Earnings TARA|FATE (Fate Therapeutics Inc) - Market Cap to Future Earnings Ratio|Forward P/E Multiple WHWK|TCRX - Projected Price to Earnings Ratio|Forward P/E Multiple CSBR (Champions Oncology, Inc.)|CVM - Projected Price to Earnings|OS Therapies - Forward P/E Multiple|Future Price to Earnings Multiple RADX (radiopharmtheranostics.com)|ARTV (artivabio.com) - Projected Price to Earnings|Adlai Nortye - Future Price to Earnings Multiple|VERU (Veru Inc.) - Forward P/E Multiple|tempesttx.com (TPST) - Market Cap to Projected Earnings|Future Price to Earnings Xilio Therapeutics, Inc. (XLO)|renovarobio.com - Price to Future Earnings Ratio|Forward P/E Multiple MURA (Mural Oncology)|KAPA - Projected Price to Earnings|OKUR: Projected Price to Earnings|Market Cap to Projected Earnings CytoMed Therapeutics GDTC|CRIS (curis.com) - Projected Price to Earnings|Price to Future Earnings Ratio APLM|THAR (Tharimmune Corp) - Forward P/E Multiple|Future Price to Earnings ADVB|Forward P/E Multiple GNPX|Market Cap to Projected Earnings calidibio.com|Sunshine Biopharma, Inc. - Projected Price to Earnings|Market Cap to Future Earnings Ratio XBIO (Xenetic Biosciences Inc.)|Salarius - Forward P/E Multiple|Kitov Pharma (PPBT) - Projected Price to Earnings|AONC: Forward P/E Multiple|beigene.com (BGNE) - Forward P/E Multiple|Future Price to Earnings Checkpoint Therapeutics, Inc.|Price to Future Earnings Ratio ELEV (elevationoncology.com)|Forward P/E Multiple ICAD|Projected Price to Earnings ikenaoncology.com IKNA|Forward P/E Multiple NTBL (Notable Labs, Ltd.)|Viracta Therapeutics Inc. (VIRX) - Projected Price to Earnings Ratio|MOR - Future Price to Earnings|Future Price to Earnings Multiple NAYA (NAYA Biosciences Inc)|AAPGV (Ascentage Pharma Group Ltd) - Projected Price to Earnings
